Advertisement

Topics

Latest Biotechnology, Pharmaceutical and Healthcare News from ChinaBio Today

07:52 EDT 23rd April 2018 | BioPortfolio

Here are the most relevant search results for "ChinaBio Today" found in our extensive news archives from over 250 global news sources.

More Information about ChinaBio Today on BioPortfolio

In addition to our news stories we have dozens of PubMed Articles about ChinaBio Today for you to read. Along with our medical data and news we also list ChinaBio Today Clinical Trials, which are updated daily. BioPortfolio also has a large database of ChinaBio Today Companies for you to search.

Showing News Articles 1–25 of 379 from ChinaBio Today

Thursday 19th April 2018

Prenetics Acquires British Consumer Genetic Testing Firm

Prenetics, an HK-based genetic testing and digital health company, announced acquisition of DNAFit, a UK-based genetic testing company. DNAFit will bring in B2C channel, adding to the B2B channel that Prenetics currently possesses. This is the first acquisition Prenetics announced after it receiving $50 million from Alibaba Hong Kong Entrepreneurs Fund and Ping An Insurance. More details.... Sha...

Wednesday 18th April 2018

Philip Partners with Digital China Health to Launch Cloud-Based Imaging Services

Royal Philips and Digital China Health launched a cloud-based imaging diagnostic assisting platform called SHINEFLY. The platform makes an integrated clinical imaging diagnostic platform – IntelliSpace Portal 9.0 available through long distance, and thus providing a flexible and customized solution to all levels of clinical institutions. More details.... Stock Symble: (NYSE: PHG, AEX: P...

Tuesday 17th April 2018

Qiming Closes $120 Million US Healthcare Fund; Two General China Funds with $1.2 Billion

Qiming Venture Partners closed three new funds with total commitments of $1.4 billion, bringing its total assets under management to $4 billion. One of the funds, the Qiming U.S. Healthcare Fund I ($120 million), will invest in early-stage US healthcare businesses. It will be based in Seattle. The other two funds, with a total of nearly $1.3 billion, are general purpose funds: one dollar based and...

Suzhou Alphamab to Start China Trial of Bispecific HER2 Inhibitor

Suzhou Alphamab was granted CFDA approval of an IND for its leading bispecific program, a HER2 inhibitor, which will be tested in patients with HER2 positive breast and gastric cancers. According to Alphamab, KN026 showed excellent binding affinity, efficacy, safety, and PK in pre-clinical tests. Initially, the company plans to start a Phase I trial in China, followed by clinical development in th...

Shuwen Biotech Reports "Multi-Million Dollar" Investment from Tasly

Shuwen Biotech, a Hangzhou diagnostics company, completed a A+ round that it described as an investment of "multi-million dollars" from Tasly Pharmaceutical Group. Shuwen aims to be the China diagnostic partner of choice for western diagnostic companies. So far, Shuwen has formed strategic partnerships with academic and commercial entities, resulting in exclusive licenses for over 20 first-in-clas...

Sunday 15th April 2018

Hong Kong Aims to be IPO Venue of Choice for Young China Life Science Companies

Innovent, Hua Medicine, Ascletis, Henlius, Shanghai Tasly, Ascentage, Grail -- each of these companies is a young, prominent China novel life science company. And each is pre-revenue, or at least pre-profit. Each one would like to stage an IPO to fund their late-stage clinical trials and commercialization. Up to now, no China-Hong Kong exchange would allow companies to IPO without a history of pro...

Saturday 14th April 2018

Week in Review: Ping An Good Doctor Plans $1 Billion Hong Kong IPO in Mid-May

Deals and Financings Ping An Good Doctor, a China mobile healthcare app, plans a $1 billion Hong Kong IPO scheduled for mid-May that values the company at $5 billion; Panacea Venture Healthcare Fund, a new China-focused venture fund led by two KPCB managing partners, filed to raise $150 million; DXY completed a $100 million Series D funding to support its online academic portal for China doctors ...

Ping An Healthcare and Technology Plans $1 Billion HK IPO for May

Ping An Insurance (Group) plans to carve out its Ping An Healthcare and Technology (also known as Ping An Good Doctor APP) and IPO in Hong Kong for $1 billion at a valuation of $5 billion. The company plans to go public in the middle of May. In May 2016, Ping An Healthcare and Technology raised $500 million in a Series A. In December 2017, the company raised $400 million from Softbank Union in a p...

Friday 13th April 2018

MabSpace Starts US Trial of PD-L1 Drug; China Trial to Begin Soon

MabSpace Biosciences of Suzhou has dosed the first patient in a US Phase I trial of MSB2311, its second generation PD-L1 treatment for advanced solid tumors. It is the first MabSpace molecule to begin clinical trials. In China, MSB2311 is in the late stages of the CFDA review process, and MabSpace expects it will start a China Phase I trial soon. Using its proprietary platform MabSpace provides di...

CANbridge to Start China Phase II/III Trial of GBM Treatment

CANbridge Life Sciences of Beijing was granted China approval of an IND to start a Phase II/III trial of its lead candidate, CAN008, in patients with glioblastoma multiforme (GBM). The approval was based on a small (10 patient) Phase I trial of CAN008 in Taiwan, an example of China-Taiwan regulatory cooperation. In the Taiwan trial, CAN008 did not show any safety problems. CAN008 is a TNF-blocker ...

Beijing's AK Medical Buys JRI Orthopedics of the UK for $24 Million

AK Medical Holdings, a Beijing orthopedic implant maker, paid $24 million to acquire JRI Orthopedics of the UK. Both companies make joint replacements. AK is the first company to obtain CFDA approval for its 3D-printed joint and spine implants in China. Three years ago, AK Medical began distributing JRI's products in China, while JRI has more recently begun manufacturing AK Medical products for us...

Thursday 12th April 2018

BeiGene Initiated Global Phase II Clinical Trial for PD-1 Antibody

BeiGene announced the initiation of a multi-center Phase II clinical trial of tislelizumab, an anti-PD-1 antibody, in patients with previously treated advanced hepatocellular carcinoma (HCC or liver cancer). [Gabbie: Technically, the "trial" can't "plan" -- only the company or people can plan] The company plans to enroll 225 patients in the Phase II trial at 75 cancer centers in Greater China (inc...

Wednesday 11th April 2018

DXY Completes $100 Million Series D Round for Academic Portal for China Doctors

DXY, the online academic portal for doctors and other life science professionals, raised $100 million in a Series D funding from undisclosed investors. According to China Money Network, the funding was conducted at a $1 billion-plus valuation, conferring Unicorn status on DXY. The eighteen-year-old site provides China doctors with up-to-date clinical and research information, as well as informatio...

Biocytogen Closes $65 Million Round for Animal Model CRO Services

Biocytogen of Beijing closed a $65 million series C funding to support its CRO operations. Founded in 2009, the company provides gene engineered animal models, preclinical animal studies and other services that include large-scale animal model supply. It also offers preclinical animal studies using gene humanized models, PDX models and reconstructed human immune system models. Biocytogen works wit...

Tuesday 10th April 2018

Bliss Biopharma of Hangzhou Licenses Cancer ADC from Morphotek

Morphotek, a US subsidiary of Japan's Eisai, granted Bliss Biopharmaceutical (Hangzhou) exclusive rights to use its eribulin-linker payload to develop a therapeutic antibody drug conjugate against an undisclosed oncology target for the China market. The eribulin-linker payload consists of a cytotoxic agent, eribulin, modified by a chemical linker to facilitate conjugation. The announcement did not...

Panacea Ventures Files to Raise $150 Million for China Healthcare

A new China-focused venture fund, Panacea Venture Healthcare Fund I, LP, filed to raise $150 million. The fund is led by two China managing partners of Kleiner Perkins Caufield & Byers (KPCB), James Huang and Hai Mi. An earlier report said the fund, which expects to make seven investments, plans to be an incubator for early-stage companies, though it would aim for quick exits through M&A o...

New World Development Invests in New Century Healthcare; Plans More China Clinics/Hospitals

New World Development, a Hong Kong conglomerate, acquired a 4.29% stake in New Century Healthcare, a China pediatric and OB-GYN medical services provider. The stake, which was acquired from another investor, is worth $30 million. According to the companies, they intend to extend their holdings in pediatric/OB-GYN medical services, adding new hospitals and clinics through internal development and a...

Sunday 8th April 2018

Denovo Starts US-China Phase III Study of Lymphoma Treatment

Denovo Biopharma, a San Diego-Hangzhou company,  has started a pivotal Phase III trial of its lead drug, DB102 (enzastaurin). DB102, which was initially developed by Eli Lilly, failed a Phase III clinical trial in 2013 in patients with diffuse large B-cell lymphoma (DLBCL). Denovo acquired global rights to DB102 in 2014, planning to redevelop the drug by targeting a sub-set of patients. By an...

Week in Review: Concord Medical Raises $240 Million for China Radiology Services

Deals and Financings  Concord Medical Services announced a $240 million private placement led by CICC Capital for its China radiation services operations; CMAB Biopharma of Suzhou raised $34 million in a Series B round led by CDBI Partners to build a GMP biologics manufacturing facility for its CDMO services; Terns Pharma, a California-Shanghai startup, in-licensed global rights to three Lil...

Saturday 7th April 2018

US-China Trade War May Affect Life Science Products

A trade war between the US and China seems imminent, with both sides threatening to impose $50 billion of tariffs, a number that quickly grew to $100 billion. At the moment, it seems as though the US will impose tariffs on products such as imported insulin, antibiotics and vitamins, among others. Experts caution that, because the threats need a few months to become effective, the tariffs may not p...

Frontage Labs, a US-China CRO, Acquires Concord Biosciences

Frontage Laboratories, a Pennsylvania-Shanghai pre-clinical CRO, acquired Concord Biosciences of Cleveland, Ohio for an undisclosed price. Concord, also a pre-clinical CRO, offers expertise in pharmaceuticals, agricultural, chemical and animal health. Frontage said the acquisition will allow it to offer a complete set of services to pharma clients, while adding agricultural products to its of...

Friday 6th April 2018

Denovo Starts US-China Phase III Study of Leukemia Treatment

Denovo Biopharma, a San Diego-Hangzhou company,  has started a pivotal Phase III trial of its lead drug, DB102 (enzastaurin). DB102, which was initially developed by Eli Lilly, failed a Phase III clinical trial in 2013 in patients with diffuse large B-cell lymphoma (DLBCL). Denovo acquired global rights to DB102 in 2014, planning to redevelop the drug by targeting a sub-set of patients. By an...

Thursday 5th April 2018

Concord Medical Announces $238 Million Investment from CCIC

Concord Medical Services announced that CICC Capital led an investment of between $238 million and $286 million in Concord’s subsidiary Beijing Meizhong Jiahe Hospital Management. The investors will hold 37.5% to 41.9% of Meizhong Jiahe's equity after the investment. Concord Medical Services Holdings Limited provides radiotherapy and diagnostic imaging services within public hospitals o...

Terns Acquires Three Lilly Candidates; Raises $30 Million from Lilly Asia Ventures

Terns Pharma, a California-Shanghai startup, in-licensed global rights to three Lilly small molecule candidates aimed at non-alcoholic steatohepatitis (NASH). Terns has its operations in Shanghai and will initially target China approval of the three candidates, with global development to follow. One year ago, Lilly Asia Ventures made an initial $30 million investment in Terns, though the company d...

China Moves to Encourage Higher Quality China-made Generic Drugs

China’s State Council announced a new initiative to bolster generic drugmakers. New rules will impose higher standards for generic drugs. If a generic drugmaker can qualify as a high-tech enterprise, the company will be eligible for tax incentives -- the normal 25% tax on corporate profits will be reduced to 15%. For the past few years, CFDA Commissioner Jingquan Bi has been cracking down on...


Advertisement
Quick Search
Advertisement
Advertisement

 

News Quicklinks